Article

NOACs and Dual Antiplatelet Therapy

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Information image
Average (ratings)
No ratings
Your rating

Abstract

On 12 November 2014, Radcliffe Cardiology, in association with Arrhythmia & Electrophysiology Review (AER) journal, held a roundtable discussion in London, UK. The discussion held between an expert group of physicians was moderated by Professor A John Camm, a renowned authority in anticoagulation and atrial fibrillation. The meeting comprised a series of seven presentations and subsequent panel discussions on a range of topical issues related to the use of non-vitamin K antagonist (novel) oral anticoagulants (NOACs): real-world versus clinical trial data; once or twice daily dosing regimens; spot checks or monitoring for anticoagulation status; antidotes for NOACs; NOACs and dual antiplatelet therapy; NOAC treatment in chronic renal impairment; and choosing between NOACs. This paper summarises the presentations and presents key highlights from the subsequent discussions.

Disclosure:Professor Camm is a consultant/advisor/speaker for Actelion, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Biotronik, BMS, ChanRX, Daiichi Sankyo, Gilead, GSK, InfoBionic, Incarda, Johnson and Johnson, Medtronic, Menarini, Merck, Mitsubishi, Novartis, Otsuka, Pfizer, Sanofi, Servier, St. Jude Medical, Takeda and Xention; Doctor Alings is a consultant/advisor for Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo; Professor De Caterina has received a research grant from Boehringer Ingelheim, and is a consultant/advisor/speaker for Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Novartis; Professor Kirchhof has received research grants from BMS/Pfizer, Cardiovascular Therapeutics, Daiichi Sankyo, Sanofi, St. Jude Medical, and is consultant/advisor/speaker for Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Johnson & Johnson, Medtronic, MSD, Pfizer and Servier; Professor Le Heuzey is a consultant/advisor for Bayer, Boehringer Ingelheim, BMS/Pfizer and Daiichi Sanyo; Professor Verheugt is consultant/advisor for Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo

Received:

Accepted:

Published online:

Support:The roundtable was supported by an unrestricted educational grant from Daiichi-Sankyo.

Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

The use of NOACs with dual antiplatelet therapy (DAPT) presents a therapeutic dilemma. There is uncertainty over the optimal antithrombotic management strategy for patients with AF presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention (PCI)/stenting.36 Professor De Caterina showed that 8–10 % of AF patients of cardiology departments develop ACS or need elective stent implantation and 15–20 % of post ACS or electively stented patients develop AF and are therefore candidates for anticoagulation.36 The use of DAPT in patients with AF after coronary stenting is essential to prevent stent thrombosis and is supported by a large body of clinical trial data; however, the use of OACs is needed to reduce the risk of stroke, and this therapeutic entity has been well-evaluated in many trials.

When used together, these therapies confer a major bleeding risk. In a Danish cohort study using national registries to identify over 82,000 patients with AF during the period 1997 to 2006 taking post-hospital therapy of warfarin, aspirin, clopidogrel and combinations of these drugs, 11.4 % developed a nonfatal or fatal bleeding over a mean 3.3 years’ follow-up, with those on triple therapy having an incidence rate of 10–13 % per patient year.37 It is therefore vital to establish an equilibrium between the risk of thrombosis (stent thrombosis and stroke) and the risk of bleeding. The ESC guidelines have stratified patients into low- and high-risk groups to minimise the time of overlap of drugs. The time of triple therapy should be as short as possible; a maximum of 1 month is recommended for the combined use of aspirin and clopidogrel, on the background of a vitamin K antagonist (VKA), with elective stenting with bare-metal stents (BMS). With drug-eluting stents (DES) in the setting of elective PCI, a maximum of 6 months and, for more recent stents, 3 months is suggested, then continuing with one single antiplatelet agent and the VKA. In the case of ACS a triple therapy overlap is advised for 6 months. The overlap should, however, be shorter in patients at high bleeding risk, in whom BMS are recommended anyhow, and in such cases the continuation of antithrombotic therapy with a VKA only is recommended after the first month. In case of patients at high bleeding risk having received stenting (usually BMS) because of an ACS, triple therapy is still restricted to 1 month, but continuing a VKA with the addition of one antiplatelet agent (clopidogrel or aspirin) up to 1 year (see Figure 3).38 A consensus document of the AHA is more complex and was not discussed here.39 However, these guidelines only cover triple therapy involving VKAs; triple therapy involving NOACs is still under investigation.

ESC Guidelines in AF patients at Moderate to High Thromboembolic Risk in whom OAC is Required

Article image

Several trials are ongoing in patients with AF and ACS and/or coronary stents. The PIONEER trial (a study exploring two strategies of rivaroxaban – 15 mg once daily + clopidogrel; 2.5 mg twice daily + DAPT for the initial 1, 6 or 12 months – versus the ‘classic’ triple therapy with a VKA + aspirin + clopidogrel in patients with AF who undergo a PCI),40 will enrol 21,000 participants. The RE-DUAL-PCI (Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting) trial will evaluate dabigatran (110 mg twice daily) + a single APT, dabigatran 150 mg twice daily + single APT and warfarin and DAPT.41 All these trials have limitations in that more than one component of the comparator ‘cocktail’ – a VKA + aspirin + clopidogrel – is being changed at a time, and the final interpretation of the data may prove difficult.

A panel discussion ensued about the need to use aspirin post-PCI. The panellists agreed that there was an excess co-prescription of these drugs and that it may be safe to use single APT with NOACs. Clopidogrel is preferred unless there is a definite stent thrombosis, according to Professor Kirchhof, in his institution, as newer agents have not been tested in patients who are anticoagulated. Patients in the RE-LY trial underwent stenting and, while bleeding rates increased, there was no difference in outcomes between warfarin and dabigatran. When performing interventions in anticoagulated patients presenting with ACS, every possible effort should be taken to prevent bleeding, e.g. a radial rather than femoral approach. The new bio-absorbable stents should minimise the need for long-term triple therapy. In conclusion, the addition of NOACs to APT may help prevent ischaemic events and stent thrombosis, but this needs testing in a clinical trial setting. It is important to balance the antithrombotic and anticoagulant effect of the different agents, but more clinical trial data are needed.

References

  1. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719–47.
    Crossref | Pubmed
  2. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094–106.
    Crossref | Pubmed
  3. Mohl W, Komamura K, Kasahara H, et al. Myocardial protection via the coronary sinus. Circ J 2008;72:526–33.
    Crossref | Pubmed
  4. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493–503.
    Crossref | Pubmed
  5. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–17.
    Crossref | Pubmed
  6. Singer DE, Hylek EM. Optimal oral anticoagulation for patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:1504.
    Crossref | Pubmed
  7. Kirchhof P, Curtis AB, Skanes AC, et al. Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 2013;34:1471–4.
    Crossref | Pubmed
  8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51.
    Crossref | Pubmed
  9. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91.
    Crossref | Pubmed
  10. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92.
    Crossref | Pubmed
  11. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104.
    Crossref | Pubmed
  12. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62.
    Crossref | Pubmed
  13. Kakkar AK, Mueller I, Bassand JP, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.
    PLoS One 2013;8:e63479.
    Crossref | Pubmed
  14. Lip GY, Laroche C, Ioachim PM, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the Eurobservational Research Programme-Atrial Fibrillation General Registry pilot phase (EORP-AF Pilot registry), Eur Heart J 2014;35:3365–76.
    Crossref | Pubmed
  15. Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the Prevention of Thromboembolic Events – European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6–14.
    Crossref | Pubmed
  16. Zamorano JL, Greiner W, Sandberg A, et al. Patient preferences for chronic treatment for stroke prevention: results from the European Patient Survey in Atrial Fibrillation (EUPS-AF). Poster P1789. Presented at European Society of Cardiology Congress, 25–29 August 2012; Munich, Germany.
  17. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010;104:633–41.
    Crossref | Pubmed
  18. Bae JP, Dobesh PP, Klepser DG, et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care 2012;18:139–46.
    Pubmed
  19. Laliberte F, Nelson WW, Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675–90.
    Crossref | Pubmed
  20. Evers T, Diamantopoulos A. Clinical impact of treatment persistence in patients with atrial fibrillation. Value in Health 2013;16:A276.
    Crossref
  21. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012;107:985–97.
    Crossref | Pubmed
  22. Douxfils J, Mullier F, Loosen C, et al. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012;130:956–66.
    Crossref | Pubmed
  23. Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban – an oral, direct and selective factor Xa inhibitor.
    J Thromb Thrombolysis 2011;32:183–7.
    Crossref | Pubmed
  24. Cuker A, Siegal DM, Crowther MA, et al. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014;64:1128–39.
    Crossref | Pubmed
  25. Blann AD, Lip GY. Laboratory monitoring of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014;64:1140–2.
    Crossref | Pubmed
  26. Makris M, Van Veen JJ, Tait CR, et al. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013;160:35–46.
    Crossref | Pubmed
  27. Phase 2 healthy volunteer study to evaluate the ability of prt064445 to reverse the effects of several blood thinner drugs on laboratory tests. Available at: http://clinicaltrials.gov/ct2/show/NCT01758432?term=NCT01758432&rank=1 (accessed 27 November 2014).
  28. Crowther M, Vandana M, Michael K, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors. Abstract no 3636. Presented at the 55th Americal Society of Haematology (ASH) Annual Meeting and Exposition 7–10 December 2013; New Orleans, LA, US.
  29. US National Institutes of Health. A study in older subject to evaluate the safety and ability of andexanet alfa to reverse the anticoagulation effect of rivaroxaban. http://clinicaltrials.gov/ct2/show/NCT02220725 (accessed 27 November 2014).
  30. US National Institutes of Health. Study to evaluate the safety, pharmacokinetics and pharmacodynamics of BI 655075 administered alone or with dabigatran etexilate. Available at: http://clinicaltrials.gov/ct2/show/NCT01688830 (accessed 27 November 2014).
  31. US National Institutes of Health. Reversal of dabigatran anticoagulant effect with idarucizumab. Available at: http://clinicaltrials.gov/ct2/show/NCT02104947 (accessed 27 November 2014).
  32. US National Institutes of Health. Effects of a double-blind, single dose of per977 administered alone, and following a single dose of edoxaban (PER977-P1). Available at: http://clinicaltrials.gov/ct2/show/NCT01826266 (accessed 27 November 2014).
  33. Boehringer Ingelheim. US FDA grants breakthrough therapy designation to Pradaxa® (dabigatran etexilate) specific investigational antidote. Press release. Available at: www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/30_june_2014_dabigatranetexilate.html (accessed 27 November 2014).
  34. van Ryn J, Sghmoll M, Pillu H, et al. Effect of dabigatran on the ability to generate fibrin at a wound site and its reversal by idarucizumab, the antidote to dabigatran, in healthy volunteers: an exploratory marker of blood loss. Abstract no 18403. Presented at the American Heart Association Scientific Sessions, 18 November 2014; Chicago, USA.
  35. Lip GY, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary – A consensus document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Eur Heart J 2010;31:1311–8.
    Crossref | Pubmed
  36. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433–41.
    Crossref | Pubmed
  37. European Heart Rhythm Association, European Association for Cardio-Thoracic Society, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369–429.
    Crossref | Pubmed
  38. Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv 2011;4:522–34.
    Crossref | Pubmed
  39. US National Institutes of Health. A study exploring two strategies of rivaroxaban (JNJ39039039; BAY-59-7939) and one of oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention. Available at: https://clinicaltrials.gov/ct2/show/NCT01830543 (accessed 17 March 2015).
  40. US National Institutes of Health. Evaluation of dual therapy with dabigatran vs. triple therapy with warfarin in patients with af that undergo a pci with stenting (REDUAL-PCI). Available at: http://clinicaltrials.gov/ct2/show/NCT02164864 (accessed 1 December 2014).
  41. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743–53.
    Crossref | Pubmed
  42. Peacock WF, Gearhart MM, Mills RM. Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol 2012;35:730–7.
    Crossref | Pubmed